关于过去,现在和未来肝脏脑病的随机对照试验的全面概述
Ovidiu-Dumitru Ilie1, Raluca Duta1, Ilinca-Bianca Nita2
1Gastroenterology Group, CENEMED Platform for Interdisciplinary Research, University of Medicine and Pharmacy "Grigore T. Popa", University Street No. 16, 700115 Iasi, Romania.
Medicina (Kaunas, Lithuania)
|December 23, 2023
概括
本次对肝脏脑病 (HE) 预防的随机对照试验 (RCT) 的综述发现,虽然针对微生物群的治疗方法很有希望,但与便微生物群移植 (FMT) 不同的是,只有益生菌和共生菌被广泛研究.
科学领域:
- 胃肠病学和肝病学
- 微生物学 微生物学
- 临床试验 研究 研究 临床试验 临床试验
背景情况:
- 肝硬化患者的肝脑病变 (HE) 有严重的后果,影响寿命和肝脏健康.
- 目前对HE的二次预防,包括rixafort,乳糖和L-ornithine L-aspartate (LOLA),可能受到个体患者微生物特征的限制.
- 了解肠道微生物组在HE中的作用对于开发有效治疗方法至关重要.
研究的目的:
- 系统地搜索和收集2000年至2023年期间发表的关于肝脑病变 (HE) 二次预防的所有随机对照试验 (RCT).
- 确定和分析与针对肠道微生物群的治疗策略相关的正在进行的RCT.
- 评估当前对高等教育微生物群调节疗法的研究环境.
主要方法:
- 在PubMed,ISI Web of Science,Scopus和ScienceDirect数据库中进行了全面的文献搜索.
- 使用受控术语和网络字符串,结合六个主要关键字来识别相关的RCT.
- 通过两个评估阶段选搜索结果,包括删除重复内容,以确定最终的研究资格.
主要成果:
- 最初的搜索结果为75个结果,其中40个 (53.34%) 在删除重复后被认为符合条件.
- 经过第二次评估,22项研究符合最终的入选资格标准.
- 在正在进行的RCT中,3项专注于便微生物群移植 (FMT),1项专注于益生菌.
结论:
- 尽管基于微生物群的策略技术进步,但对高血压预防的研究仍然不均.
- 在过去十年中,益生菌和共生菌是对HE进行最广泛研究的微生物向干预措施.
- 需要进一步的研究,特别是RCT,以探索像FMT这样的疗法在治疗肝脑病变方面的潜力.
更多相关视频
08:54Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke
Published on: June 6, 2025
271
09:48Quantification of Neurovascular Protection Following Repetitive Hypoxic Preconditioning and Transient Middle Cerebral Artery Occlusion in Mice
Published on: May 4, 2015
13.8K
相关概念视频
01:12Hazard Ratio
129
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
129
01:30Electroconvulsive Therapy
41
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
41